Mohammad Khursheed Siddiqi
Overview
Explore the profile of Mohammad Khursheed Siddiqi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majid N, Siddiqi M, Hassan M, Malik S, Khan S, Khan R
Biomater Adv
. 2023 May;
151:213450.
PMID: 37148596
Aggregation of physiologically synthesized soluble proteins to insoluble, cytotoxic fibrils is a pre-requisite for pathogenesis of amyloid associated disorders including Alzheimer's disease, non-systemic amyloidosis, Parkinson's disease, etc. Considerable advancement has...
2.
Malik S, Siddiqi M, Naseem N, Nabi F, Masroor A, Majid N, et al.
Biochimie
. 2023 Mar;
211:110-121.
PMID: 36958592
Protein aggregation is an underlying cause of many neurodegenerative diseases. Also, the overlapping pathological disturbances between neurodegenerative diseases and type-2 diabetes mellitus have urged the scientific community to explore potential...
3.
Gupta N, Quazi S, Jha S, Siddiqi M, Verma K, Sharma S, et al.
Nutrients
. 2022 Nov;
14(22).
PMID: 36432511
Chickpea seeds are the source of proteins in human nutrition and attribute some nutraceutical properties. Herein, we report the effects of chickpea seed bioactive peptide on albumin, insulin, lactoglobulin and...
4.
Hromadkova L, Siddiqi M, Liu H, Safar J
Cells
. 2022 Oct;
11(19).
PMID: 36230957
Recent findings of diverse populations of prion-like conformers of misfolded tau protein expand the prion concept to Alzheimer's disease (AD) and monogenic frontotemporal lobar degeneration (FTLD)-MAPT P301L, and suggest that...
5.
Majid N, Siddiqi M, Alam A, Malik S, Ali W, Khan R
Int J Biol Macromol
. 2022 Sep;
221:900-912.
PMID: 36096254
Amyloidopathies are the consequence of misfolding with subsequent aggregation affecting people worldwide. Irrespective of speedy advancement in the field of therapeutics no agent for treating amyloidopathies has been discovered and...
6.
Malik S, Zaidi N, Siddiqi M, Majid N, Masroor A, Salam S, et al.
Colloids Surf B Biointerfaces
. 2022 May;
216:112563.
PMID: 35588684
Protein aggregation leads to several human pathologies such as Alzheimer's disease (AD), type 2 diabetes (T2D), Parkinson's disease (PD), etc. Due to the overlap in the mechanisms of type 2...
7.
Siddiqi M, Kim C, Haldiman T, Kacirova M, Wang B, Bohon J, et al.
PLoS Pathog
. 2021 Jun;
17(6):e1009642.
PMID: 34138981
There is a limited understanding of structural attributes that encode the iatrogenic transmissibility and various phenotypes of prions causing the most common human prion disease, sporadic Creutzfeldt-Jakob disease (sCJD). Here...
8.
On the binding reaction of loratadine with human serum acute phase protein alpha 1-acid glycoprotein
Almutairi F, Ajmal M, Siddiqi M, Alalawy A, Khan R
J Biomol Struct Dyn
. 2021 Jun;
40(19):9484-9491.
PMID: 34121623
Loratadine is an important anti-allergic drug. It is a second generation antihistamine drug used to treat allergic rhinitis, hay fever and urticaria. Human serum alpha 1-acid glycoprotein (AG) is an...
9.
Almutairi F, Ajmal M, Siddiqi M, Majid N, Ahmad Al-Alawy A, Abdelhameed A, et al.
J Biomol Struct Dyn
. 2020 Apr;
39(5):1525-1534.
PMID: 32308140
Interaction of levocabastine with human serum albumin (HSA) is investigated by applying fluorescence spectroscopy, circular dichroism spectroscopy and molecular docking methods. Levocabastine is an important drug in treatment of allergy...
10.
Siddiqi M, Majid N, Malik S, Alam P, Khan R
Subcell Biochem
. 2020 Jan;
93:471-503.
PMID: 31939162
Amyloid diseases are of major concern all over the world due to a number of factors including: (i) aging population, (ii) increasing life span and (iii) lack of effective pharmacotherapy...